Where Merck KGAA’s Pipeline Stands
Pipeline review resulted in new focus and products with high value, exec explains.
You may also be interested in...
Threshold Pharmaceuticals’ lead compound from its hypoxia-activated prodrug platform, TH-302, is partnered with Merck KGaA on one Phase III program and in internal development for another Phase III.
A discussion with internal and external experts restarts clinical development of atacicept for lupus after a two-year hiatus.
Merck Serono will conduct a second Phase III study of lung cancer vaccine tecemotide in patients treated concurrently with chemotherapy and radiation. The START trial, which also dosed patients receiving sequential therapy, failed but the predefined, concurrently treated subgroup showed greater median overall survival compared to placebo.